Thiazolidinedione effects on blood pressure in diabetic patients with metabolic syndrome treated with glimepiride

Hypertension Research

Volumn 28, Issue 11, 2005, Pages 917-924

  Derosa, Giuseppe ^c   Cicero, Arrigo Francesco Giuseppe ^a   D'Angelo, Angela ^c   Gaddi, Antonio ^a   Ragonesi, Pietro Dario ^b   Piccinni, Mario Nello ^c   Salvadeo, Sibilla ^c   Ciccarelli, Leonardina ^c   Pricolo, Fabio ^c   Ghelfi, Morena ^c   Ferrari, Ilaria ^c   Montagna, Lorenza ^c   Fogari, Roberto ^c  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b SAN CARLO BORROMEO HOSPITAL   (Italy)

^c UNIVERSITY OF PAVIA   (Italy)

Author keywords

Glimepiride; Metabolic syndrome; Pioglitazone; Rosiglitazone; Thiazolidinediones

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; GLIMEPIRIDE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; ROSIGLITAZONE;

ADULT; ARTICLE; BLOOD PRESSURE REGULATION; BODY MASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DIET THERAPY; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RESPONSE; FEMALE; FLATULENCE; GLUCOSE BLOOD LEVEL; HEADACHE; HEART RATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERTENSION; INSULIN BLOOD LEVEL; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; METABOLIC SYNDROME X; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE;

BLOOD GLUCOSE; BLOOD PRESSURE; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES;

EID: 31744442785     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1291/hypres.28.917     Document Type: Article

References (33)

1. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: American Diabetes Association: clinical practice recommendations 2002. Diabetes Care 2002; 25 (Suppl): S1-S147.
2. Charpentier G, Fleury F, Kabir M, Vaur L, Halimi S: Improved glycaemic control by addition of glimepiride to metformin monotherapy in type 2 diabetic patients. Diabet Med 2001; 18: 828-834.
3. Riddle M: Combining sulfonylureas and other oral agents. Am J Med 2000; 108 (Suppl 6a): 15S-22S.
4. McCall AL: Clinical review of glimepiride. Expert Opin Pharmacother 2001; 2: 699-713.
5. Ovalle F, Ovalle-Berúmen JF: Thiazolidinediones: a review of their benefits and risks. South Med J 2002; 95: 1187-1194.
6. Wolffenbuttel BH, Gomis R, Squatrito S, Jones NP, Patwardhan RN: Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in type 2 diabetic patients. Diabet Med 2000; 17: 40-47.
7. Vongthavaravat V, Wajchenberg BL, Waitman JN, et al, 125 Study Group: An international study of the effects of rosiglitazone plus sulphonylurea in patients with type 2 diabetes. Curr Med Res Opin 2002; 18: 456-461.
8. St John Sutton M, Rendell M, Dandona P, et al: A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes. Diabetes Care 2002; 25: 2058-2064.
9. Pavo I, Jermendy G, Varkonyi TT, et al: Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes. J Clin Endocrinol Metab 2003; 88: 1637-1645.
10. National Cholesterol Education Program (NCEP) Expert Panel: Summary of the third report of the NCEP expert panel on detection, evaluation, and treatment of high blood cholesterol (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
11. Derosa G, Cicero AFG, Gaddi A, et al: Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial. Clin Ther 2004; 26: 744-754.
12. American Diabetes Association: Nutrition recommendations and principles for people with diabetes mellitus (position statement). Diabetes Care 2001; 24 (1): S44-S47.
13. American Diabetes Association: Screening for diabetes (position statement). Diabetes Care 2001; 24 (1): S21-S24.
14. Guidelines Subcommittee: 1999 World Health Organization-International Society of Hypertension Guidelines for the management of hypertension. J Hypertens 1999; 17: 151-183.
15. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
16. Bunn HF, Gabbay HK, Gallop PM: The glycosylation of haemoglobin. Relevance to diabetes mellitus. Science 1978; 200: 21-27.
17. European Diabetes Policy Group: A desktop guide to type 2 diabetes mellitus. Diabet Med 1999; 16: 716-730.
18. Heding LG: Determination of total serum insulin (IRI) in insulin-treated diabetic patients. Diabetologia 1972; 8: 260-266.
19. Winer BJ: Statistical Principles in Experimental Design, 2nd ed. New York, McGraw-Hill, 1971.
20. Beckman JA, Creager MA, Libby P: Diabetes and atherosclerosis. Epidemiology, pathophysiology, and management. JAMA 2002; 287: 2570-2581.
21. Vivian EM, Rubinstein GB: Pharmacologic management of diabetic nephropathy. Clin Ther 2002; 24: 1741-1756.
22. Katayama S, Inaba M, Morita T, Awata T, Shimamoto K, Kikkawa R: Blood pressure control in Japanese hypertensives with or without type 2 diabetes mellitus. Hypertens Res 2000; 23: 601-605.
23. Nishina M, Kikuchi T, Yamazaki H, Kameda K, Hiura M, Uchiyama M: Relationship among systolic blood pressure, serum insulin and leptin, and visceral fat accumulation in obese children. Hypertens Res 2003; 26: 281-288.
24. Anan F, Takahashi N, Ooie T, Yufu K, Saikawa T, Yoshimatsu H: Role of insulin resistance in nondipper essential hypertensive patients. Hypertens Res 2003; 26: 669-676.
25. Hirose H, Saito I, Kawabe H, Saruta T: Insulin resistance and hypertension: seven-year follow-up study in middle-aged Japanese men (the KEIO study). Hypertens Res 2003; 26: 795-800.
26. Harano Y, Suzuki M, Shinozaki K, et al: Clinical impact of insulin resistance syndrome in cardiovascular diseases and its therapeutic approach. Hypertens Res 1996; 9 (Suppl 1): S81-S85.
27. Derosa G, Ragonesi PD, Mugellini A, Ciccarelli L, Fogari R: Effects of telmisartan compared with eprosartan on blood pressure control, glucose metabolism and lipid profile in hypertensive, type 2 diabetic patients: a randomized, double-blind, placebo-controlled 12-month study. Hypertens Res 2004; 27: 457-464.
28. Boyle PJ, King AB, Olansky L, et al: Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records. Clin Ther 2002; 24: 378-396.
29. Kim JI, Tsujino T, Fujioka Y, Saito K, Yokoyama M: Bezafibrate improves hypertension and insulin sensitivity in humans. Hypertens Res 2003; 26: 307-313.
30. Kanbay M, Yildirir A, Bozbas H, et al: Statin therapy helps to control blood pressure levels in hypertensive dyslipidemic patients. Ren Fail 2005; 27: 297-303.
31. Shargorodsky M, Wainstein G, Gavish E, Leibovitz Z, Maras D, Zimlichman R: Treatment with rosiglitazone reduces hyperinsulinemia and improves arterial elasticity in patients with type 2 diabetes mellitus. Am J Hypertens 2003; 16: 617-622.
32. Fullert S, Schneider F, Haak E, et al: Effects of pioglitazone in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study. J Clin Endocrinol Metab 2002; 87: 5503-5506.
33. Derosa G, Mugellini A, Ciccarelli L, Crescenzi G, Fogari R: Comparison between repaglinide and glimepiride in patients with type 2 diabetes mellitus: a one-year, randomized, double-blind assessment of metabolic parameters and cardiovascular risk factors. Clin Ther 2003; 25: 472-484.